Advertisement

Journal of Gastrointestinal Cancer

, Volume 41, Issue 4, pp 248–253 | Cite as

DNMT3B −579 G>T Promoter Polymorphism and Risk of Gallbladder Carcinoma in North Indian Population

  • Kshitij Srivastava
  • Anvesha Srivastava
  • Balraj MittalEmail author
Original Research

Abstract

Aim

Carcinoma of gallbladder (GBC) is a relatively rare but highly fatal disease. The DNA (cytosine-5-)-methyltransferase 3 beta (DNMT3B) −579 G>T promoter polymorphism (rs1569686) influences gene function and has been associated with various malignancies. Present population-based case-control study was undertaken to examine the potential association of DNMT3B −579 G>T variation with GBC in North Indian population.

Methods

Genotypes and allelic frequencies of the DNMT3B −579 G>T polymorphism were determined for 212 GBC patients and 219 controls using PCR-RFLP. Odds ratio (OR) and 95% confidence interval (95% CI) were calculated for the association of DNMT3B polymorphism with GBC. Analysis of potential transcription factor binding sites was also identified in the region harboring the polymorphism.

Results

The DNMT3B −579 G>T polymorphism was found to be non-significantly associated with an overall increased risk of GBC (OR = 1.10 and 1.56 for T/G and G/G genotypes, respectively, P trend = 0.227). The increased risk was predominant in both male and female cohorts and also non-significantly in GBC patients with gallstone status (OR = 1.44; P = 0.280, OR = 1.06; P = 0.804 and OR = 1.45; P = 0.143, respectively).

Conclusion

DNMT3B −579 G>T polymorphism may alter susceptibility to GBC although it may not play a major role in the pathoetiology of this disease in North Indian population.

Keywords

gallbladder cancer (GBC) DNA (cytosine-5-)-methyltransferase 3 beta (DNMT3Bepidemiology polymorphism restriction fragment length polymorphism (RFLP) 

Notes

Acknowledgement

The study was supported by fellowship grants from Counsel of Scientific and Industrial Research (CSIR) and Department of Science and Technology (DST), Government of India.

Declaration of Competing Interests

The author(s) declare that they have no competing interests.

References

  1. 1.
    Lazcano-Ponce EC, Miquel JF, Munoz N, Herrero R, Ferrecio C, Wistuba II, et al. Epidemiology and molecular pathology of gallbladder cancer. CA Cancer J Clin. 2001;51:349–64.CrossRefPubMedGoogle Scholar
  2. 2.
    Hoi-Hung C, Tin-Lap L, Owen MR, Wai-Yee C. DNA methylation of cancer genome Birth Defects Research Part C: Embryo Today. Reviews. 2009;87:335–50.Google Scholar
  3. 3.
    Yen RW, Vertino PM, Nelkin BD, Yu JJ, el-Deiry W, Cumaraswamy A, et al. Isolation and characterization of the cDNA encoding human DNA methyltransferase. Nucleic Acids Res. 1992;20:2287–91.CrossRefPubMedGoogle Scholar
  4. 4.
    Xie S, Wang Z, Okano M, Nogami M, Li Y, He WW, et al. Cloning, expression and chromosome locations of the human DNMT3 gene family. Gene. 1999;236:87–95.CrossRefPubMedGoogle Scholar
  5. 5.
    Bestor TH. The DNA methyltransferases of mammals. Hum Mol Genet. 2000;9:2395–402.CrossRefPubMedGoogle Scholar
  6. 6.
    Roll JD, Rivenbark AG, Jones WD, Coleman WB. DNMT3b overexpression contributes to a hypermethylator phenotype in human breast cancer cell lines. Mol Cancer. 2008;7:15.CrossRefPubMedGoogle Scholar
  7. 7.
    Tian Z, Zhang ZY, Li L, Li J (2006) [Expression of DNA methyltransferases in salivary adenoid cystic carcinoma and its association with the CpG islands methylation of tumor suppressor genes] Zhonghua Kou Qiang Yi Xue Za Zhi 41:411–415Google Scholar
  8. 8.
    Vallbohmer D, Brabender J, Yang D, Schneider PM, Metzger R, Danenberg KD, et al. DNA methyltransferases messenger RNA expression and aberrant methylation of CpG islands in non-small-cell lung cancer: association and prognostic value. Clin Lung Cancer. 2006;8:39–44.CrossRefPubMedGoogle Scholar
  9. 9.
    Xiong Y, Dowdy SC, Xue A, Shujuan J, Eberhardt NL, Podratz KC, et al. Opposite alterations of DNA methyltransferase gene expression in endometrioid and serous endometrial cancers. Gynecol Oncol. 2005;96:601–9.CrossRefPubMedGoogle Scholar
  10. 10.
    Yakushiji T, Uzawa K, Shibahara T, Noma H, Tanzawa H. Over-expression of DNA methyltransferases and CDKN2A gene methylation status in squamous cell carcinoma of the oral cavity. Int J Oncol. 2003;22:1201–7.PubMedGoogle Scholar
  11. 11.
    Guo X, Zhang L, Wu M, Wang N, Liu Y, Er L, et al. Association of the DNMT3B polymorphism with colorectal adenomatous polyps and adenocarcinoma. Mol Biol Rep. 2010;37:219–25.CrossRefPubMedGoogle Scholar
  12. 12.
    Hong YS, Lee HJ, You CH, Roh MS, Kwak JY, Lee MJ, et al. DNMT3b 39179GT polymorphism and the risk of adenocarcinoma of the colon in Koreans. Biochem Genet. 2007;45:155–63.CrossRefPubMedGoogle Scholar
  13. 13.
    Lee SJ, Jeon HS, Jang JS, Park SH, Lee GY, Lee BH, et al. DNMT3B polymorphisms and risk of primary lung cancer. Carcinogenesis. 2005;26:403–9.CrossRefPubMedGoogle Scholar
  14. 14.
    Wang L, Rodriguez M, Kim ES, Xu Y, Bekele N, El-Naggar AK, et al. A novel C/T polymorphism in the core promoter of human de novo cytosine DNA methyltransferase 3B6 is associated with prognosis in head and neck cancer. Int J Oncol. 2004;25:993–9.PubMedGoogle Scholar
  15. 15.
    Fan H, Liu DS, Zhang SH, Hu JB, Zhang F, Zhao ZJ. DNMT3B 579 G > T promoter polymorphism and risk of esophagus carcinoma in Chinese World. J Gastroenterol. 2008;14:2230–4.Google Scholar
  16. 16.
    International Union Against Cancer (UICC) (2002) TNM classification of malignant tumours, 6th ed, Sobin LH, Wittekind Ch (ed.), New York, Wiley-Liss:pp. 184–187Google Scholar
  17. 17.
    Devlin B, Roeder K. Genomic control for association studies. Biometrics. 1999;55:997–1004.CrossRefPubMedGoogle Scholar
  18. 18.
    Armitage P. Tests for linear trends in proportions and frequencies. Biometrics. 1995;11:375–86.CrossRefGoogle Scholar
  19. 19.
    Brennan P. Gene-environment interaction and aetiology of cancer: what does it mean and how can we measure it? Carcinogenesis. 2002;23:381–7.CrossRefPubMedGoogle Scholar
  20. 20.
    Campbell MJ, Julious SA, Altman DG. Estimating sample sizes for binary, ordered categorical, and continuous outcomes in two group comparisons. BMJ. 1995;311:1145–8.PubMedGoogle Scholar
  21. 21.
    Wacholder S, Chanock S, Garcia-Closas M, El Ghormli L, Rothman N. Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst. 2004;96:434–42.CrossRefPubMedGoogle Scholar
  22. 22.
    Grabe N. AliBaba2: context specific identification of transcription factor binding sites. In Silico Biol. 2002;2:S1–15.PubMedGoogle Scholar
  23. 23.
    Thompson JD, Higgins DG, Gibson TJ. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucl Acids Res. 1994;22:4673–80.CrossRefPubMedGoogle Scholar
  24. 24.
    National Cancer Registry Programme (2002) Two-year report of the Population Based Cancer Registries 1997–1998. New Delhi: Indian Council of Medical ResearchGoogle Scholar
  25. 25.
    Hsing AW, Sakoda LC, Rashid A, Andreotti G, Chen J, Wang BS, et al. Variants in inflammation genes and the risk of biliary tract cancers and stones: a population-based study in China. Cancer Res. 2008;68:6442–52.CrossRefPubMedGoogle Scholar
  26. 26.
    Srivastava A, Srivastava K, Pandey S, Choudhuri G, Mittal B. Single-nucleotide polymorphisms of DNA repair genes OGG1 and XRCC1: association with gallbladder cancer in North Indian population. Ann Surg Oncol. 2009;16:1695–703.CrossRefPubMedGoogle Scholar
  27. 27.
    Srivastava K, Srivastava A, Pandey S, Kumar A, Mittal B. Functional polymorphisms of the cyclooxygenase (PTGS2) gene and risk for gallbladder cancer in a North Indian population. J Gastroenterol. 2009;44:774–80.CrossRefPubMedGoogle Scholar
  28. 28.
    Park SK, Andreotti G, Sakoda LC, Gao YT, Rashid A, Chen J, et al. Variants in hormone-related genes and the risk of biliary tract cancers and stones: a population-based study in China. Carcinogenesis. 2009;30:606–14.CrossRefPubMedGoogle Scholar
  29. 29.
    Jones PA, Laird PW. Cancer epigenetics comes of age. Nat Genet. 1999;21:163–7.CrossRefPubMedGoogle Scholar
  30. 30.
    Baylin SB, Herman JG. DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet. 2000;16:168–74.CrossRefPubMedGoogle Scholar
  31. 31.
    Yanagisawa Y, Ito E, Yuasa Y, Maruyama K. The human DNA methyltransferases DNMT3A and DNMT3B have two types of promoters with different CpG contents. Biochim Biophys Acta. 2002;1577:457–65.PubMedGoogle Scholar
  32. 32.
    Diehl AK. Gallstone size and the risk of gallbladder cancer. JAMA. 1983;250:2323–6.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Kshitij Srivastava
    • 1
  • Anvesha Srivastava
    • 1
  • Balraj Mittal
    • 1
    Email author
  1. 1.Department of GeneticsSanjay Gandhi Post Graduate Institute of Medical SciencesLucknowIndia

Personalised recommendations